Home       About       Policy Forums       Interest Groups       Annual Meeting       Awards       Journal       Membership

WIM GOETTSCH

NETHERLANDS 2019-22​

Wim Goettsch, PhD is currently Special Advisor HTA at the Dutch National Health Care Institute. He was the Director of the EUnetHTA JA3 (2016-2020) Directorate and Chair of the Executive Board of EUnetHTA between June 2016 and March 2018. Since 2019, he has held a position as an Associate Professor at Utrecht University (NL), where he is leading a new H2020 consortium called HTx, New Methods for Health Technology Assessment (2019-2024) with fifteen partners around Europe. Between 2010 and 2015, he was the Project Leader of Work Package 5 of EUnetHTA Joint Action 1 & 2, in which rapid joint assessments of relative effectiveness of pharmaceuticals were piloted between more than 25 HTA organisations around Europe.

Between 2010 and 2013, he was the Deputy Secretary of the Medicinal Products Reimbursement Committee at Dutch National Health Care Institute. He is currently a member of the HTAi Policy Forum Committee and has been Director in the Board (2013-2015) of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Before joining the National Health Care Institute, he worked as a research manager for the PHARMO Institute and was responsible for the coordination of numerous pharmacoepidemiological and outcomes studies for international offices of pharmaceutical companies such as AstraZeneca, Novartis, Pfizer and GSK.

He also worked as a senior epidemiologist in the field of antimicrobial resistance for the National Institute for Public Health and the Environment in the Netherlands and was involved in the initiation of the European Antimicrobial Resistance Surveillance Network (EARS-Net) that is now coordinated by the ECDC. He was also seconded as a scientific secretary for Dutch National Health Council on the topic of antimicrobial growth promotors in animal feed (1997-1998). He has a PhD in immunology and an advanced education in pharmaco- epidemiology and pharmaco-economics. He has more than 70 publications in peer-reviewed international journals.

HTAi is The ONLY Global Society Championing Equitable, Responsive, And Cutting-Edge Health Technology Assessment (HTA). As a community of multidisciplinary advisors, academics, scientists, professionals, public & private organizations, students, and citizen members.Everything we do is dedicated to better health for all people and the future of HTA worldwide.

Become A Member Today

    Copyright © 2021. All Rights Reserved.